Company / PP&E (Net)
Protagonist Therapeutics, Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$3.9M
FY2025
5-year range
$1.2M / $3.9M
FY2021-FY2025
Trend
+21.0%
vs FY2024
Sector context
#116 of 193
Health Care
What the data says
At $4M, Protagonist Therapeutics, Inc.'s pp&e (net) ranks #116 of 193 in the Health Care sector. PP&E (Net) has fluctuated over the past 10 years, ranging from $562,000 in FY2016 to $4M in FY2025.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of +21.4%.
Improved from $1M to $4M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +35.1%
- 5-Year CAGR
- +21.4%
- 10-Year CAGR
- -
Sector benchmark
#116 of 193 in Health CareTop 60% of 193This company $3.9M Sector average $777.6M
▼
-99.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.4%, indicating consistent growth.
- In FY2025, pp&e (net) increased 21.0% year-over-year.
- Ranks #116 out of 193 companies in the Health Care sector.
- Lowest pp&e (net) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 4.66 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.9M | +21.0% |
| FY2024 | $3.2M | +166.9% |
| FY2023 | $1.2M | -23.6% |
| FY2022 | $1.6M | -13.0% |
| FY2021 | $1.8M | +23.0% |
| FY2020 | $1.5M | -13.0% |
| FY2019 | $1.7M | +95.2% |
| FY2018 | $861.0K | -2.0% |
| FY2017 | $879.0K | +56.4% |
| FY2016 | $562.0K | -7.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026